Perrigo reports weak second-quarter earnings amid sudden chief executive departure
Perrigo's abrupt leadership transition and declining second-quarter margins cast doubt on the sustainability of its high dividend yield and long-term turnaround strategy.
Perrigo (NYSE: PRGO) reported a sharp decline in second-quarter 2026 profitability alongside the abrupt departure of its chief executive officer. The private-label generic drugmaker installed an interim leader while searching for a permanent replacement, adding operational uncertainty to a period of financial contraction.
Core sales decreased 3.1 percent year over year, while organic sales fell 3.5 percent during the period. Core earnings dropped nearly 21 percent to $0.46 per share, pressured by a 2.5 percentage point decline in adjusted gross margin and a 1.6 percentage point drop in adjusted operating margin.
Despite the earnings contraction, the company maintained its $0.29 per share dividend, which remains covered by core profits. This payout supports an equity yield of approximately 8.3 percent, a figure that reflects market skepticism regarding the company's future cash flow generation rather than a simple income opportunity.
Perrigo manufactures over-the-counter medications, primarily supplying store-brand generics to retail partners who lack their own manufacturing facilities. Theoretically, elevated inflation should drive consumers toward these lower-cost alternatives to protect their household budgets, but the anticipated volume shift failed to materialize in the most recent quarter.
This recent miss highlights a persistent structural challenge, as the company's top-line revenue has trended lower for more than a decade. Investors must now evaluate whether the business can reverse this prolonged decline while managing significant leadership turnover at the executive level.
Interim President and Chief Executive Officer Albert Manzone pointed to ongoing restructuring efforts during the earnings release. "We continued to execute our Three-S plan in the second quarter, strengthening areas of the business within our control, improving operational performance, streamlining our portfolio, and further reducing debt," Manzone stated.
However, the simultaneous deterioration in both gross and operating margins suggests these operational improvements are not yet flowing through to the bottom line. The elevated equity yield signals that the market is pricing in substantial dividend risk if margin compression continues.
Market professionals will be watching closely to see if the interim leadership can stabilize profitability before the next earnings cycle.
